As HER2 is expressed in 30% of oesophageal squamous cell carcinomas (ESCCs), T-cell-based immunotherapy and monoclonal antibodies targeted against HER2 are attractive, novel approaches for ESCCs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback